Sheroy Minocherhomji

Sheroy Minocherhomji

Auto-generated profile, based on publicly available information

Sheroy Minocherhomji

Eli Lilly and Company

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
CVCharles C. Valentine
Charles C. Valentine
RYRobert R. Young
Robert R. Young
MFMark R. Fielden
Mark R. Fielden
RKRohan Kulkarni
Rohan Kulkarni
LWLindsey N. Williams
Lindsey N. Williams
JSJesse J Salk
Jesse J Salk
The ability to accurately measure mutations is critical for basic research and identifying potential drug and chemical carcinogens. Current methods for in vivo quantification of mutagenesis are limited because they rely on transgenic rodent systems that are low-throughput, expensive, prolonged, and do not fully represent other species such as humans. Next-generation sequencing (NGS) is a conceptually attractive alternative for detecting mutations in the DNA of any organism; however, the limit of resolution for standard NGS is poor. Technical error rates (∼1 × 10−3) of NGS obscure the true abundance of somatic mutations, which can exist at per-nucleotide frequencies ≤1 × 10−7. Using duplex sequencing, an extremely accurate error-corrected NGS (ecNGS) technology, we were able to detect mutations induced by three carcinogens in five tissues of two strains of mice within 31 d following exposure. We observed a strong correlation between mutation induction measured by duplex sequencing and the gold-standard transgenic rodent mutation assay. We identified exposure-specific mutation spectra of each compound through trinucleotide patterns of base substitution. We observed variation in mutation susceptibility by genomic region, as well as by DNA strand. We also identified a primordial marker of carcinogenesis in a cancer-predisposed strain of mice, as evidenced by clonal expansions of cells carrying an activated oncogene, less than a month after carcinogen exposure. These findings demonstrate that ecNGS is a powerful method for sensitively detecting and characterizing mutagenesis and the early clonal evolutionary hallmarks of carcinogenesis. Duplex sequencing can be broadly applied to basic mutational research, regulatory safety testing, and emerging clinical applications. Significance Error-corrected next-generation sequencing (ecNGS) can be used to rapidly detect and quantify the in vivo mutagenic impact of environmental exposures or endogenous processes in any tissue, from any species, at any genomic location. The greater speed, higher scalability, richer data outputs, and cross-species and cross-locus applicability of ecNGS compared to existing methods make it a powerful new tool for mutational research, regulatory safety testing, and emerging clinical applications.

15 April 2017 in Genes & Development
Verified
Journal Article
Open access
PDF file
TNToyoaki Natsume
Toyoaki Natsume
KNKohei Nishimura
Kohei Nishimura
SMSheroy Minocherhomji
Sheroy Minocherhomji
RBRahul Bhowmick
Rahul Bhowmick
IHIan D. Hickson
Ian D. Hickson
MKMasato Kanemaki
Masato Kanemaki
DNA replication fork progression can be disrupted at difficult to replicate loci in the human genome, which has the potential to challenge chromosome integrity. This replication fork disruption can lead to the dissociation of the replisome and the formation of DNA damage. To model the events stemming from replisome dissociation during DNA replication perturbation, we used a degron-based system for inducible proteolysis of a subunit of the replicative helicase. We show that MCM2-depleted cells activate a DNA damage response pathway and generate replication-associated DNA double-strand breaks (DSBs). Remarkably, these cells maintain some DNA synthesis in the absence of MCM2, and this requires the MCM8–9 complex, a paralog of the MCM2–7 replicative helicase. We show that MCM8–9 functions in a homologous recombination-based pathway downstream from RAD51, which is promoted by DSB induction. This RAD51/MCM8–9 axis is distinct from the recently described RAD52-dependent DNA synthesis pathway that operates in early mitosis at common fragile sites. We propose that stalled replication forks can be restarted in S phase via homologous recombination using MCM8–9 as an alternative replicative helicase.

8 November 2025 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
CYCarole L. Yauk
Carole L. Yauk
ALAnthony M. Lynch
Anthony M. Lynch
VDVasily N. Dobrovolsky
Vasily N. Dobrovolsky
MSMaik Schuler
Maik Schuler
SSStephanie L. Smith-Roe
Stephanie L. Smith-Roe
FMFrancesco Marchetti
Francesco Marchetti
Error-corrected sequencing (ECS) is a transformative method for in vivo mutagenicity assessment, enabling direct, highly sensitive measurement of mutation frequency and spectrum. ECS addresses key limitations of the transgenic rodent (TGR) assay, including lack of integration into standard toxicity studies, restricted model availability, and limited alignment with the 3R principles. To support regulatory acceptance, an expert workgroup of the International Workshops on Genotoxicity Testing (IWGT) reviewed ECS technologies and developed consensus recommendations for its inclusion into Organisation for Economic Co-operation and Development (OECD) test guidelines. The working group agreed that ECS: produces results that are concordant with validated TGR assays; can be incorporated into standard ≥28-day repeat-dose toxicity studies; and, data interpretation should be based on overall mutation frequency compared with concurrent vehicle controls. The working group emphasized harmonized data reporting aligned with OECD principles and endorsed study designs that enable quantitative risk assessment. Overall, the working group agreed that ECS offers a significant advancement over current mutagenicity assays by enabling the use of diverse models beyond conventional TGR systems described in OECD test guideline 488. The working group fully supports the application of ECS to generate in vivo mutagenicity data for regulatory submissions and recommends its inclusion in future OECD test guidelines.

4 June 2026 in International Journal of Toxicology
Verified
Journal Article
Closed access
SMSheroy Minocherhomji
Sheroy Minocherhomji
KSKatie Sokolowski
Katie Sokolowski
KFKelle Franklin
Kelle Franklin
LLLaura Leung
Laura Leung
EBEileen Blasi
Eileen Blasi
TKTae-Won Kim
Tae-Won Kim
Advances in the delivery and safety of nucleic acid-based therapeutics are enabling tissue-selective targeting and broadening the reach of genetic medicines. In addition to GalNAc-conjugated oligonucleotides, newer modalities—predominantly antibody- and peptide-conjugated oligonucleotides—combine innovative components with complex and often multimodal mechanisms of action. These constructs may require tailored nonclinical testing strategies to evaluate pharmacology, biodistribution, and component- and construct-driven toxicities. Here, we review the current state of these molecules, collectively termed here as b io c onjugated o ligonucleotide (BCO) therapeutics, summarize key safety liabilities across the protein scaffold, linker, and oligonucleotide payload, and highlight nonclinical approaches, including predictive safety assessments and in vivo toxicity studies that can support human clinical trials. We also discuss risk-based regulatory considerations that may differ from traditional biologics or small molecules.